CGTLive®’s Weekly Rewind – April 5, 2024
Review top news and interview highlights from the week ending April 5, 2024.
CGTLive Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. First US Patient With Hemophilia B Receives Gene Therapy
Val-rox was approved as Roctavian in December 2023.
2. Shalini Shenoy, MD, MBBS, on Comparing Treatment Options for Sickle Cell Disease
The director of the Stem Cell Transplant & Cellular Therapy Program at St. Louis Children’s Hospital discussed when the choice should be made to transition from symptom management to curative therapies.
3. Verve Moves on to Second Gen Cardiovascular CRISPR Therapy After Adverse Events
The sixth participant dosed experienced grade 3 treatment-induced ALT increases and thrombocytopenia.
4. Mitchell Horwitz, MD, on Cost-Effectiveness of Omidubicel for Allo-HCT
The professor of medicine at Duke Cancer Institute discussed uptake and research with the cord blood therapy since its approval.
5. Kyverna’s CAR T Seems Feasible in Multiple Sclerosis
KYV-101 is also being evaluated in lupus nephritis, myasthenia gravis, and systemic sclerosis.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy
November 21st 2024In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.
